

## REFERENCES

1. Firestein G.S, Klippel J.H and Dieppe P.A. (1997). Rheumatoid synovitis and pannus. *Rheumatology*. Mosby. London. pp. 5/13.1-5/13.5.
2. Mulherin D, Fitzgerald O and Bresnihan B. (1996). Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. *Arthritis Rheumatoid*. 39, 115-124.
3. Demaziere A. (1993). Macrophages in rheumatoid synovial membrane: an update. *Rev. Rhum*. 60, 568-579.
4. Mor A, Abramson SB and Pillinger MH. (2005). The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. *Clinical Immunology*. 115, 118-128.
5. Roomi M.W, Ivanov V, Niedzwiecki A, Rath M and Matthias Rath. Cancer Research Division, Santa Clara, CA. Anti-Angiogenic Effect of Nutrient Synergy on Human Synovial Sarcoma Cell Line SW982 (Online). Available: <http://jn.nutrition.org/cgi/content/full/134/12/3521S> (2009, Oct 30)
6. Dorling Kindersley., (2007) JOINTS (online). Available: <http://www.factmonster.com/dk/science/encyclopedia/skeletal-system.html> (2009, Nov 3).
7. Brommer E.J, Dooijewaard G, Dijkmans B.A and Breedveld F.C. (1992). Plasminogen activators in synovial fluid and plasma from patients with arthritis. *Ann. Rheum. Dis*. 51, 965-968.

8. Muller-Ladner U, Gay RE and Gay S. (2001). Structure and function of synoviocytes, in: W.J. Koopman (Ed.). *Arthritis and Allied Conditions—A Textbook of Rheumatology*, 14th ed., Lippincott-Williams and Wilkins, Philadelphia. pp. 243-251.
9. Edwards J.C.W. (1997). The synovium, in: J.H. Klippel, P.A. Dieppe (Eds.), *Rheumatology*. Mosby. London. pp. 5/6.1- 5/6.8.
10. Qu Z, Garcia C.H, O'Rourke L.M, Planck S.R, Kohli M and Rosenbaum J.T. (1994). Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. *Arthritis Rheum.* 37, 212-220.
11. Kramer I, Wilbulswas A, Croft D and Genot E. (2003). Rheumatoid arthritis: targeting the proliferative fibroblast, *Prog. Cell Cycle Res.* 5, 59-70.
12. Mohr W, Beneke G and Mohing W. (1975). Proliferation of synovial lining cells and fibroblasts. *Ann. Rheum. Dis.* 34, 219-224.
13. Taisuke Yamazaki *et al.* (2003). Phenotype characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone. *In Vitro Cell. Dev. Biol-Animal.* 39, 337-339.
14. Taisuke Yamazaki *et al.* (2005). Effect of dexamethasone on binding activity of transcription factors nuclear factor-kB and activating protein-1 in SW982 human synovial sarcoma cells. *In Vitro Cell. Dev. Biol-Animal.* 41, 80-82.
15. David M Lee, Michael E and Weinblatt. (2001). Rheumatoid arthritis. *THE LANCET*. Vol 358. September 15.

16. Chaiwongsa R. Effect of Plai (*Zingiber Cassumunar* Roxb.) extract on hyaluronan and proteoglycan degradation in cartilage explants. M.S. Thesis, Chiang Mai university, 2004.
17. Fabris M et al. (2005). Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraproline expression. *J Rheumatol.* 32, 998-1005.
18. Nucleus Medical Art, Inc., (2008) Rheumatoid Arthritis. (Online) Available: <http://www.beliefnet.com/healthandhealing/getcontent.aspx?cid=11593> (2009 Nov,3).
19. Ernest H.S, Choy M.D, Gabriel S and Panayi M.D, Sc.D. (2001). Cytokine pathway and joint inflammation in rheumatoid arthritis. *N Engl J Med.* Vol. 344. No. 12. March 22, 2001.
20. Fraser JR, Laurent TC, Laurent UB. (1997). Hyaluronan: its nature, distribution, functions and turnover. *J Intern Med.* 242, 27-33
21. Itano N, et al. (1999). Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. *J Biol Chem.* 274(35), 25085-25092.
22. Robert Stern. (2004). Hyaluronan catabolism: a new metabolism pathway. *Eur. J. Cell Biol.* 83, 317-325.
23. Vince Hascall and Jeffrey D. Esko. (2009) Hyaluronan. (Online). Available: <http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=glyco2&part=ch15> (2009, Nov 3)

24. Andrew P. Spicer and John A. McDonald. (1998) Eukaryotic Hyaluronan synthesis. (Online). Available: <http://www.glycoforum.gr.jp/science/hyaluronan/hapdf/HA07.pdf> (2009, Sep 7)
25. Knudson CB, Knudson W. (1993). Hyaluronan-binding proteins in development, tissue homeostasis, and disease. *Faseb.* 7, 1233–41.
26. Rilla K, Lammi MJ, Sironen R, Torronen K, Luukkonen M, Hascall VC, *et al.* (2002). Changed lamellipodial extension, adhesion plaques and migration in epidermal keratinocytes containing constitutively expressed sense and antisense hyaluronan synthase 2 (Has2) genes. *J Cell Sci.* 115(Pt 18), 3633–43.
27. Itano N, Atsumi F, Sawai T, Yamada Y, Miyaishi O, Senga T, *et al.* (2002). Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. *Proc Natl Acad Sci USA.* 99 (6), 3609–14.
28. Laurent TC, Laurent UB and Fraser JR. (1996). The structure and function of hyaluronan: an overview. *Immunol Cell Biol.* 74, A1–7.
29. Yasui T, Akatsuka M, Tobetto K and Ando T. (1992). The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. *Agents Actions.* 37(1–2), 155–156.
30. Akatsuka M, Yamamoto Y, Tobetto K, Yasui T and Ando T. (1993). In vitro effects of hyaluronan on prostaglandin E2 induction by interleukin-1 in rabbit articular chondrocytes. *Agents Actions.* 38(1–2), 122–125.

31. Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. (2006). High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. *Osteoarthritis Cartilage*. 14, 1237–1247.
32. Homandberg GA, Hui F, Wen C, Kuettner KE and Williams JM. (1997). Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: I. In vitro. *Osteoarthritis Cartilage*. 5, 309–319.
33. Williams JM, Plaza V, Hui F, Kuettner KE and Homandberg GA. (1997). Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: II. In vivo. *Osteoarthritis Cartilage*. 5(4), 235–40.
34. Gotoh S, Onaya J, Abe M, Miyazaki K, Hamai A, Horie K, *et al.* (1993). Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. *Ann Rheum Dis*. 52, 817–822.
35. Pozo MA, Balazs EA, Belmonte C. (1997). Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. *Exp Brain Res*. 116(1),3–9.
36. Da-Wei Zhang, Quan-Sheng Yang, Jin-Yu Zhu, Xiao-Rui Cao, Li-Wen Li and Qing-Sheng Zhu. (2007). Amelioration of osteoarthritis by intra-articular hyaluronan synthase 2 gene therapy. *Medical Hypotheses*. 69, 1111–1113.

37. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, and Simon J.C. (2002). Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. *J. Exp. Med.* 195, 99–111.
38. Taylor K. R, Trowbridge J. M, Rudisill J. A, Termeer C. C, Simon J. C, and Gallo R. L. (2004). Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. *J. Biol. Chem.* 279, 17079–17084.
39. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon M. C, Soler-Ranger L, Fuentes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, *et al.* (2005). Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. *J. Immunol.* 174, 3032-3040.
40. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, and Noble. (2005). PW Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nature Medicine.* 11, 1173-9.
41. Kristen R, Taylor, Kenshi Yamasaki, Katherine A. Radek, Anna Di Nardo, Heidi Goodarzi, Douglas Golenbock, Bruce Beutler, and Richard L. Gallo. (2007). Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. *J Biol Chem.* 282, 18265–18275.

42. Luke AJ O' Neill. (2005). Toll-like receptor act as mediator of injury or repair in the inflamed lung, and the balance depends on the integrity of a component of the extracellular matrix. *Nature*. 11, 1173-1179.
43. Perola O. Magalhaes, Andre M. Lopes, Priscila G. Mazzola, Carlota Rangel-Yagui, Thereza C. V. Penna and Adalberto Pessoa Jr. (2007). Methods of endotoxin removal from biological preparations: a Review. *J Pharm Pharmaceut Sci* .10, 388-404.
44. Tanamoto K, Zahringer U, Mckenzie G.R, Galanos C, Rietschel E.T, Luderitz O, Kusumoto S and Shiba T. (1984). Biological activities of synthetic lipid A analogues: pyrogenicity, lethal toxicity, anticomplement activity and induction of gelation of limulus amoebocyte lysate. *Infect. Immun*. 44, 421-426.
45. Hirschfield M, Ma Y, Weis J.H, Vogel S.N and Weis J.J. (2000). Cuttingedge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2, *J. Immunol*. 165, 618–622.
46. Hirschfield M, Weis J.J, Toschchakov V, Salkowski C.A, Cody M.J, Ward D.C, Quereshi N, Michalek S.M and Vogel S.N. (2001). Signalling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. *Infect. Immun*. 69, 1477–1482.
47. Takeshi Oguchi and Naoki Ishiguro. (2004). Differential stimulation of three forms of hyaluronan synthase by TGF- $\beta$ , IL-1 $\beta$  and TNF- $\alpha$ . *Connective tissue research*. 45, 197-205.

48. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H and Kawai S. (2003). Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. *Arthritis Rheum.* 48, 2819-2828.
49. Smeets T.J.M, Kraan M.C and van Loon M.E. (2003). Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial cells, *Arthritis Rheum.* 48, 2155-2162.
50. Morel J.C and Park C.C. (2002). Signal transduction pathways involved in rheumatoid synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression, *J. Biol. Chem.* 277, 34679– 34691.
51. Miranda-Carus M.E, Balsa A, Benito-Miguel M, Perez de Ayala C and Martin-Mola E. (2004). IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. *J. Immunol.* 173, 1463-1476.
52. Jungel A, Distler J.H, Kurowska-Stolarska M, Seemayer C.A, Seibl R, Forster A, Michel B.A, Gay R.E, Emmrich F, Gay S and Distler O. (2004). Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. *Arthritis Rheum.* 50, 1468-1476.

53. Hwang S.Y, Kim J.Y, Kim K.W, Park M.K, Moon Y, Kim W.U and Kim H.Y. (2004). IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Aktdependent pathways. *Arthritis Res. Ther.* 6, 120-128.
54. Akira S. *et al.* (2006). Pathogen recognition and innate immunity. *Cell.* 124, 783-801.
55. Masahiro Yamamoto and Shizuo Akira. (2005). Mechanisms of innate immune responses mediated by Toll-like receptors. *Clinical and Applied Immunology Reviews* 5, 167-183.
56. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, *et al.* (1994). Bacterial endotoxin: molecular relationships of structure to activity and function. *FASEB J.* 8, 217-225.
57. Hailman E, Lichenstein HS, Wurfel MM *et al.* (1994). Lipopolysaccharide (LPS)- binding protein accelerates the binding of LPS to CD14. *J Exp Med.* 179, 269-277.
58. Tobias PS, Soldau K, Gegner JA, Mintz D and Ulevitch RJ. (1995). Lipopolysaccharide (LPS)-binding protein-mediated complexation of lipopolysaccharide with soluble CD14. *J Biol Chem.* 279, 10482-10488.
59. Shimazu R, *et al.* (1999). MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. *J Exp Med.* 189(11), 1777-82.

60. Visintin A, Mazzoni A, Spitzer JA and Segal DM. (2001). Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. *Proc Natl Acad Sci USA*. 98(21), 12156-12161.
61. Schromm AB, *et al.* (2001). Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. *J Exp Med*. 194,79-88.
62. Beutler B. (2004). Inferences, questions and possibilities in Toll-like receptor signalling. *Nature*. 430, 257-63.
63. Beutler B, Hoebe K, Georgel P and Tabet K. (2005). Genetic analysis of innate immunity: identification and function of the TIR adapter proteins. *Adv Exp Med Biol*. 560, 29-39.
64. Dahl LB, Dahl IM, Engstrom-Laurent A and Granath K.(1985). Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. *Ann Rheum Dis*. 44(12), 817-22.
65. Anthony L DeFranco, Richard M Locksley and Miranda Robertson. (1999-2007). The Toll-Like Receptor Family of Innate Immune Receptors. (Online) Available: <http://www.new-science.com/content/pdf/nsp-immunity-3-10.pdf> (2009, Oct 30)
66. Watters M, Elaine F Kenny and Luke A J O Neill. (2007). Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. *Immunology and Cell Biology*. 85, 411–419

67. Ralf R. Schumann, Claus Belka, Dirk Reuter, Norbert Lamping, Carsten J. Kirschning, Joerg R. Weber and Dagmar Pfeil. (1998). Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial Cells. *Blood*. 91, 577-584.
68. II Singer, S Scott, J Chin, EK Bayne, G Limjuco, J Weidner, DK Miller, K Chapman and MJ Kostura. (1995). The interleukin-1 beta-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immunoelectron microscopy. *Journal of Experimental Medicine*. 182, 1447-1459.
69. Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A., and Jongeneel, C. V. (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. *J. Exp. Med.* 171, 35-47
70. Danis V.A., Kulesz A.J., Nelson D.S. and Brooks P.M. (1990). The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes *in vitro*: variation in healthy subjects and patients with arthritis. *Clin. exp. Immunol.* 79, 335-340
- ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright © by Chiang Mai University  
All rights reserved

71. Jian Li, Xing Long, Jin Ke, Qing-Gong Meng, Winson C.C. Lee, Jacinta M. Doocey and Fan Zhu. (2008). Regulation of HAS expression in human synovial lining cells of TMJ by IL-1 $\beta$ . *Archives of oral biology*. 53, 60-65.
72. Makoto Kawakami, Kimihiro Suzuki, Yasunori Matsuki, Toshiaki Ishizuka, Toshihiko Hidaka, Tatsuya Konishi, Mitsuyo Matsumoto, Koji Kataharada and Haruo Nakamura. (1998). Hyaluronan production in human rheumatoid fibroblastic synovial lining cells is increased by interleukin 1 $\alpha$  but inhibited by transforming growth factor  $\alpha$ 1. *Ann Rheum Dis*. 57, 602–605.
73. Giuseppe M. Campo, Angela Avenoso, Salvatore Campo, Angela D'Ascola, Alida M. Ferlazzo and Alberto Calatroni. (2006). TNF- $\alpha$ , IFN- $\gamma$ , and IL-1 $\beta$  modulate hyaluronan synthase expression in human skin fibroblasts: Synergistic effect by concomital treatment with FeSO<sub>4</sub> plus ascorbate. *Molecular and Cellular Biochemistry* 292, 169–178.
74. Tschopp, Fabio Martinon & Kimberly Burns. (2003). NALPs: a novel protein family involved in inflammation. *Nature Reviews Molecular Cell Biology*. 4, 95–104.
75. Day R, Quinn D, March L, Graham G and Williams K. (2000). NSAIDA and analogesics. In: Gray S, Firestein GS, Panayi GS, Wollheim FA, editor. Rheumatoid arthritis frontiers in pathogenesis and treatment. New York: Oxford University Press, Inc.

76. Alan K, Matsumoto M.D, Joan Bathon, M.D. and Clifton O. Bingham III, M.D. (2009). Rheumatoid Arthritis Treatment. (Online) Available: [http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum\\_treat.html](http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_treat.html) (2009, Sep 28)
77. Riel PL and Kroot EJ. (2000). Gold, antimalarials, sulfasalazine and other DMARDs. In: Gray S. Firestein GSPaFAW, editor. Rheumatoid Arthritis Frontiers in pathogenesis and treatment. New York: Oxford university Press, Inc.
78. Ministry of Public Health. Department of Medical Sciences Vol.1. (1995) Thai Herbal Pharmacopoeia pp.51-56.
79. Jeenapomgsa R. *et al.* (2003). Anti-inflammatory Activity of (E)-1-(3,4-dimethoxyphenyl)butadiene from *Zingiber cassumunar* Roxb. *J Ethnopharm.* 87, 143-148.
80. Amatayakul T. *et al.* (1979). Chemistry and crystal structures of some constituents of *Zingiber cassumunar*. *Aust J Chem.* 32, 71-88.
81. Tuntiwachwuttikul P. *et al.* (1980). Syntheses of some constituents *Zingiber cassumunar*. *Aust J Chem.* 33, 913-916.
82. Kuroyanagi M. *et al.* (1980). Further characterization of the constituents of a Thai medicinal plant, *Zingiber cassumunar* Roxb. *Chem Pharm Bull.* 28, 2948-2959.
83. Dinter H. *et al.* (1980). The structures of Cassumunaquinones 1 and 2 from *Zingiber cassumunar*. *Z Naturforsch.* 35, 154-155.

84. Pongprayoon U. *et al.* (1996/97). Topical anti-inflammatory activity of the major Lipophilic constituents of the rhizome of *Zingiber cassumunar* Part II: Hexane extractives. *Phytomedicine*. 3(4), 323-326.
85. ICS-Unido. (2009) *Zingiber cassumunar* Roxburgh. (Online). Available: [http://www.ics.trieste.it/MAPs/MedicinalPlants\\_Plant.aspx?id=665](http://www.ics.trieste.it/MAPs/MedicinalPlants_Plant.aspx?id=665) (2009, Sep 7)
86. Pothacharoen P, Choochip K, Pitak T, Pompimon W, Premanode B, Hardingham TE and Kongtawelert P. (2006) Effect of *Alpinia galangal* extract on cartilage degradation and gene expression in human chondrocyte and synovial fibroblast metabolism. *Central European Journal of Biology*. 1,335-342.
87. Ahmed S, Pakozdi A and Koch AE. (2006). Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activity by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum*. 54, 2393-23401.
88. Pothacharoen P. The quantitative analysis of chondroitin sulfate epitope and hyaluronan as diagnostic markers for degenerative joint diseases by ELISA technique. M.S. Thesis, Chiang Mai university, 2000.
89. วรวิทย์ เล่าห์เรณู. โรคข้ออักเสบรูมาตอยด์. เชียงใหม่: ชนบรรณการพิมพ์; 2546.
90. Nishida Y, Knudson CB, Kuettner KE, Knuson W. (2000). Osteogenic protein-1 promotes the synthesis and retention of extracellular matrix within bovine articular cartilage and chondrocyte cultures. *Osteoarthritis Cartilage*. 8, 127-136.

91. Engstrom-Laurent A, and Hallgren R. (1987). Circulating hyaluronic acid level vary with physical activity in health subjects and in rheumatoid arthritis patients: Relationship to synovitis mass and morning stiffness. *Arthritis Rheum.* 30, 1333-1338.
92. Jacobson A, Brinck J, Briskin M.J, Spicer A.P and Heldin P. (2000). Expression of human hyaluronan synthase in response to external stimuli. *Biochemical Journal.* 348, 29-35.
93. Sugiyama Y, Shimada A, Sayo T, Saki S and Inoue S. (1998). Putative hyaluronan synthase mRNA are expressed in mouse skin and TGF-beta upregulates their expression in culture human skin cells. *J. Invest. Dermatol.* 110, 116-121.
94. Kojima F, Naraba H, Y. Sasaki, Beppu M, Aoki H and Kawai S. (2003). Prostaglandin E2 is an enhancer of interleukin-1beta-induce expression membrane-associated prostaglandin E syntase in rheumatoid synovial fibroblasts. *Arthritis Rheum.* 48, 2819–2828.
95. Smeets T.J.M, Kraan M.C and van Loon M.E. (2003) Tumor necrosis factor a blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial cells. *Arthritis Rheum.* 48, 2155–2162.
96. Viriyakhasem N. Effects of pinocembrin on the expression of matrix metalloproteinases and involved signaling pathway in synovial fibroblasts. M.S. Thesis, Chiang Mai university, 2008.

97. Muzio M, Natoli G, Saccani S, Levrero M and Mantovani A. (1998) The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). *J. Exp. Med.* 187, 2097-2101.
98. Kaback LA and Smith TJ. (1999). Expression of hyaluronan synthase messenger ribonucleic acid and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. *J. Clin. Endocrinol Metab.* 84, 4079-4084.
99. Ijuin C, Ohno S, Tanimoto K, Honda K and Tanne K. (2001). Regulation of hyaluronan synthase gene expression in human periodontal ligament cells by tumor necrosis factor-alpha, interleukin-1beta and interferon-gamma. *Arch Oral Biol.* 46, 767-772.
100. Tanimoto K, Ohno S, Fujimoto K *et al.* (2001). Proinflammatory cytokines regulate the expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. *Connect Tissue Res.* 42, 187-195.
101. Hayflick L. (1965). The limited *in vitro* lifetime of human diploid cell strains. *Exp Cell Res.* 37, 614-36.
102. Roman Dziarski, Qiuling Wang, Kensuke Miyake, Carsten J. Kirschning and Dipika Gupta. (2001). MD-2 enables Toll-like Receptor 2 (TLR-2)-mediated responses to lipopolysaccharide and enables TLR2-mediated responses to gram-positive and gram-negative bacteria and their cell wall component. *The journal of immunology.* 166, 1938-1944.

103. Sinead M. Miggin, Eva Palsson-McDermott, Aisling Dunne, Caroline Jefferies, Emmanuel Pinteaux, Kathy Banahan, Caroline Murphy, Paul Moynagh, Masahiro Yamamoto, Shizuo Akira, Nancy Rothwell, Douglas Golenbock, Katherine A. Fitzgerald, and Luke A. J. O'Neill. (2006). NF- $\kappa$ B activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1. *PNAS*. 104, 3372-3377.
104. Nagaya H., Ymagata T., Ymagata S., Iyoda K., Ito H., Hasegawa Y. and Iwata H. (1999). Examination of synovial fluid and serum hyaluronidase activity as a joint marker in rheumatoid arthritis and osteoarthritis patients (by zymography). *Ann Rheum Dis*. 58, 186–188.
105. Rossler A. and Hinghofer-Szalkay H. (2003). Hyaluronan fragment: an information-carrying system. *Horm Metab Res*. 35, 67-68.